AstraZeneca
CEO Pascal Soriot on Tuesday reiterated the pharmaceutical firm’s commitment to the U.S. market amid reports that he is considering shifting its listing stateside.
Soriot said the U.K.-listed company had many reasons to be in the U.S., adding that it was “rapidly transferring manufacturing” across the Atlantic so it could serve all U.S. patient needs domestically.
“We have lots of reasons to be here [in the U.S.],” Soriot told media during an earnings call.
“This country [the U.S.] will represent, we hope, 50% of our revenue by 2030. We have thousands of employees … across the country,” he added.
